SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FET is drawing attention amid a renewed move higher and broader interest in AI-focused crypto tokens, with traders pointing to Fetch.ais autonomous-agent theme and accumulating on pullbacks. The reaction is bullish but cautious: some see a breakout developing, while others say FET needs to clear resistance and remains vulnerable to Bitcoin and wider altcoin weakness.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 molecular-profiling and external-control analyses for Verastems ovarian-cancer combination are drawing attention, especially evidence of activity in KRAS wild-type patients and the possibility of a broader treatment opportunity. Traders are weighing the encouraging findings against frustration that the stock has not responded more strongly, while looking ahead to the VS-7375 clinical update.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for a choppy rebound and consolidation near a closely watched price threshold, with traders sharing bullish accumulation and breakout hopes. Others remain skeptical, citing prolonged sideways action, limited utility, and doubts that token burns can meaningfully reduce supply.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budgets $650 million settlement with Pentwater has renewed attention on the hedge funds role in the stocks earlier dramatic short squeeze, with some traders speculating about another squeeze. Others argue that heavy debt and weak earnings make the rally fragile.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives proposed tokenomics change, which traders say could double INJs deflation rate through increased burns, is fueling supply-squeeze talk alongside optimism about its RWA and on-chain finance activity. Many holders are bullish and accumulating, while skeptics point to the tokens prolonged weakness and question whether the fundamentals will translate into demand.

OpenAI

OpenAIs confidential draft S-1 filing has fueled attention around a potential IPO, with traders speculating about its timing and the impact on related private-market holdings. Enthusiasm over a major listing is tempered by skepticism about valuation, losses, and whether the company will move ahead soon.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is drawing attention as its shares slide toward multi-year lows despite a sizable cash balance, with investors debating whether EMT-2 trial results and the still-pending LR-EtEPA patent can restore value. Frustrated holders point to generic competition and managements record, while more optimistic traders see potential in the clinical and patent catalysts.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgos OpenAI collaboration and reported autonomous-lab resultsincluding a 40% reduction in cell-free protein synthesis costshave fueled renewed interest in its AI-and-lab-automation pivot. Bulls see evidence the platform may deliver real efficiency gains, while skeptics question whether the technology can translate into meaningful revenue amid the companys history of losses and execution challenges.

USELESS

Discussion centers on USELESSs volatile meme-coin momentum, with bullish traders urging dip-buying and citing supposed whale accumulation while anticipating another breakout. Others point to sharp drops, selling and the tokens speculative nature.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ais fiscal first-quarter results and outlook are driving discussion: bulls point to improving bookings, positive cash flow and restructuring progress, while bears focus on declining revenue, weak guidance and continued losses. High short interest also fuels speculation about a squeeze, but the turnaround case remains contested.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SMLR Outstanding article that hits the mark on SMLR&#39;s current state. So if you want to refresh your SMLR insights or learn about SMLR from scratch, this is a must read. https://everyticker.com/quote/SMLR/analysis/semler-scientific-a-bitcoin-treasury-masquerading-as-a-medical-device-company-nasdaq-smlr

Bert

Semler Scientific has completed a radical transformation from medical device manufacturer to Bitcoin treasury company, but the healthcare business that was supposed to fund this strategy is collapsing...

EveryTicker

Semler Scientific: A Bitcoin Treasury Masquerading as a Medical Device Company (NASDAQ:SMLR) - SMLR Stock Analysis

StockTwits Web

Semler Scientific Inc

 Outstanding article that hits the mark on SMLR's current state. So if you want to refresh your SMLR insights or learn about SMLR from scratch, this is a must read. 